(BPT) - Excessive bone density loss can lead to a condition called osteoporosis, which significantly increases a person’s risk for fracture. Women specifically can lose up to 20 percent of their bone ...
Osvyrti and Jubereq are FDA-approved denosumab biosimilars for osteoporosis and cancer-related skeletal events, interchangeable with Prolia and Xgeva, respectively. Clinical trials confirmed ...
Osvyrti is suppled as a 60mg/mL single-dose prefilled syringe for SC administration and Jubereq is supplied as 120mg/1.7mL single-dose vial for SC administration.
Accord Healthcare today announced the launch of Osvyrti (denosumab), a biosimilar to Prolia® (Amgen), and Jubereq (denosumab) ...
Dr. Reddy’s and Alvotech have entered into a license and supply agreement for the commercialization of AVT03, Alvotech’s biosimilar candidate to Prolia and Xgeva (denosumab). The collaboration ...
On November 24, 2025, Alvotech announced that the European Commission (EC) has approved AVT03 as a biosimilar to Amgen’s PROLIA® and ...
Sandoz has obtained the Food and Drug Administration’s clearance for Wyost (denosumab-bbdz) and Jubbonti (denosumab-bbdz), the only FDA-approved denosumab biosimilars, to treat all indications of ...
DUBLIN, Jan. 30, 2020 /PRNewswire/ -- The "Women's Health Care Market by Drugs (Prolia, Xgeva, Evista, Mirena, Zometa, Reclast, Nuvaring, Primarin, Actonel ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback